<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>RRM Academy Research Library</title>
    <link>https://rrmacademy.org/library/</link>
    <description>The latest additions to the RRM Academy Research Library: curated research on restorative reproductive medicine, NaProTechnology, fertility awareness-based methods, endometriosis, PCOS, and reproductive surgery.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 18 Jun 2026 22:45:00 GMT</lastBuildDate>
    <atom:link href="https://rrmacademy.org/library/rss.xml" rel="self" type="application/rss+xml" />
    <item>
      <title><![CDATA[Prospective of low dose naltrexone use in treatment of autoimmune pathology and endometriosis]]></title>
      <link>https://rrmacademy.org/library/prospective-of-low-dose-naltrexone-use-in-treatment-of-autoimmune-pathology-and--vky7pat0/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/prospective-of-low-dose-naltrexone-use-in-treatment-of-autoimmune-pathology-and--vky7pat0/</guid>
      <description><![CDATA[Golianovskyi OV, Andrienko OO, Furman OV, Boyle P -- Reproductive Endocrinology (2020)

There are still many complex issues in the management of autoimmune pathologies in gynecology and reproductology, endometriosis in particular. Naltrexone, a competitive antagonist of opiate receptors in the central and peripheral nervous systems, reveals new qualities such as effects on autoimmune processes. Naltrexone in low doses of 1.7–5 mg (Low Dose Naltrexone, LDN) revealed the opposite effect on opiate receptors in the form of a rebound effect and, as a consequence, a strong increase in…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:45:00 GMT</pubDate>
      <dc:creator><![CDATA[Golianovskyi OV, Andrienko OO, Furman OV, Boyle P]]></dc:creator>
      <category>Endometriosis</category>
    </item>
    <item>
      <title><![CDATA[The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain]]></title>
      <link>https://rrmacademy.org/library/the-use-of-lowdose-naltrexone-ldn-as-a-novel-antiinflammatory-treatment-for-chro-xjvpgsbw/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/the-use-of-lowdose-naltrexone-ldn-as-a-novel-antiinflammatory-treatment-for-chro-xjvpgsbw/</guid>
      <description><![CDATA[Younger J, Parkitny L, McLain D -- Clinical Rheumatology (2014)

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's better-known activity on opioid receptors. As a daily oral…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:21 GMT</pubDate>
      <dc:creator><![CDATA[Younger J, Parkitny L, McLain D]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[The Utilization of Low Dose Naltrexone for Chronic Pain]]></title>
      <link>https://rrmacademy.org/library/the-utilization-of-low-dose-naltrexone-for-chronic-pain-xexywnge/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/the-utilization-of-low-dose-naltrexone-for-chronic-pain-xexywnge/</guid>
      <description><![CDATA[Poliwoda S, Noss B, Truong GTD, Creech ZA, Koushik SS, Urits I, Viswanath O -- CNS Drugs (2023)

Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not only shown with opioid abuse. In 1984 this drug was also approved for alcohol abuse. Naltrexone…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:20 GMT</pubDate>
      <dc:creator><![CDATA[Poliwoda S, Noss B, Truong GTD, Creech ZA, Koushik SS, Urits I, Viswanath O]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Utilization of Low-Dose Naltrexone for Burning Mouth Syndrome: A Case Report]]></title>
      <link>https://rrmacademy.org/library/utilization-of-lowdose-naltrexone-for-burning-mouth-syndrome-a-case-report-apiwnrrm/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/utilization-of-lowdose-naltrexone-for-burning-mouth-syndrome-a-case-report-apiwnrrm/</guid>
      <description><![CDATA[Neuman DL, Chadwick AL -- A&amp;A Practice (2021)

Burning mouth syndrome is a chronic pain condition characterized by a burning sensation of the oropharynx. The pathophysiology of burning mouth syndrome includes peripheral and central sensitization. Treatment is generally aimed at symptom reduction. We describe a woman in her seventh decade with burning mouth syndrome that had been refractory to treatment for nearly a decade. Low-dose naltrexone has been reported to provide analgesia in central sensitization states and was successful in…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:18 GMT</pubDate>
      <dc:creator><![CDATA[Neuman DL, Chadwick AL]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low-dose naltrexone for treatment of burning mouth syndrome]]></title>
      <link>https://rrmacademy.org/library/lowdose-naltrexone-for-treatment-of-burning-mouth-syndrome-ve2ddzbr/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/lowdose-naltrexone-for-treatment-of-burning-mouth-syndrome-ve2ddzbr/</guid>
      <description><![CDATA[Sangalli L, Miller CS -- Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology (2023)

Objective: The International Classification of Disease defines burning mouth syndrome (BMS) as a chronic intraoral burning sensation, with no identifiable local or systemic cause. Since current management is often unsatisfactory, the aim of this report is to describe a new treatment modality (i.e., low-dose naltrexone [LDN]).

Study design: A 62-year-old woman presented with the complaint of burning on the tongue of 3 years' duration. Existing comorbidities were fibromyalgia, irritable bowel…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:17 GMT</pubDate>
      <dc:creator><![CDATA[Sangalli L, Miller CS]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low-dose naltrexone as a treatment for chronic fatigue syndrome]]></title>
      <link>https://rrmacademy.org/library/lowdose-naltrexone-as-a-treatment-for-chronic-fatigue-syndrome-lh30idct/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/lowdose-naltrexone-as-a-treatment-for-chronic-fatigue-syndrome-lh30idct/</guid>
      <description><![CDATA[Bolton MJ, Chapman BP, Van Marwijk H -- BMJ Case Reports (2020)

Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue,…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:15 GMT</pubDate>
      <dc:creator><![CDATA[Bolton MJ, Chapman BP, Van Marwijk H]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia]]></title>
      <link>https://rrmacademy.org/library/the-use-and-utility-of-lowdose-naltrexone-capsules-for-patients-with-fibromyalgi-0h0z9ze8/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/the-use-and-utility-of-lowdose-naltrexone-capsules-for-patients-with-fibromyalgi-0h0z9ze8/</guid>
      <description><![CDATA[Cote B, Ross B, Fortner J, Rao D -- International journal of pharmaceutical compounding (2018)

Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive dysfunction. With few U.S. Food and Drug Administration-approved treatment options, there is evidence that low-dose naltrexone, an opioid antagonist approved for opioid and alcohol dependence at high doses, may have efficacy in the treatment of fibromyalgia and chronic pain. At the doses required for fibromyalgia treatment, naltrexone needs to be compounded, and no data…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:14 GMT</pubDate>
      <dc:creator><![CDATA[Cote B, Ross B, Fortner J, Rao D]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series]]></title>
      <link>https://rrmacademy.org/library/lowdose-naltrexone-ldn-for-chronic-pain-at-a-single-institution-a-case-series-lsmwph2p/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/lowdose-naltrexone-ldn-for-chronic-pain-at-a-single-institution-a-case-series-lsmwph2p/</guid>
      <description><![CDATA[McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V -- Journal of Pain Research (2023)

Purpose: Low-dose naltrexone (LDN) has increased in popularity as a non-opioid medication that may decrease chronic pain symptoms. LDN is most commonly used to treat fibromyalgia, complex regional pain syndrome (CRPS), and painful diabetic neuropathy. Other studies suggest that LDN provides general symptom reduction in inflammatory conditions such as Crohn's disease and multiple sclerosis. We reviewed our experience with patients to whom we have prescribed LDN to see what types of painful…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:12 GMT</pubDate>
      <dc:creator><![CDATA[McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study]]></title>
      <link>https://rrmacademy.org/library/effective-doses-of-lowdose-naltrexone-for-chronic-pain-an-observational-study-jfl827nd/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/effective-doses-of-lowdose-naltrexone-for-chronic-pain-an-observational-study-jfl827nd/</guid>
      <description><![CDATA[Marcus N, Robbins L, Araki A, Gracely E, Theoharides T -- Journal of Pain Research (2024)

Purpose: Despite the availability of a wide variety of analgesics, many patients with chronic pain often experience suboptimal pain relief in part related to the absence of any medication to address the nociplastic component of common pain syndromes. Low-dose naltrexone has been used for the treatment of chronic pain, typically at 4.5 mg per day, even though it is also noted that effective doses of naltrexone for chronic pain presentations range from 0.1 to 4.5 mg per day. We performed an…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:11 GMT</pubDate>
      <dc:creator><![CDATA[Marcus N, Robbins L, Araki A, Gracely E, Theoharides T]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Is Fibromyalgia An Endocrine/Endorphin Deficit Disorder? Is Low Dose Naltrexone a New Treatment Option?]]></title>
      <link>https://rrmacademy.org/library/is-fibromyalgia-an-endocrineendorphin-deficit-disorder-is-low-dose-naltrexone-a--ecf6omfn/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/is-fibromyalgia-an-endocrineendorphin-deficit-disorder-is-low-dose-naltrexone-a--ecf6omfn/</guid>
      <description><![CDATA[Ramanathan S, Panksepp J, Johnson B -- Psychosomatics (2012)]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:08 GMT</pubDate>
      <dc:creator><![CDATA[Ramanathan S, Panksepp J, Johnson B]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low‐dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double‐blind, placebo‐controlled, counterbalanced, crossover trial assessing daily pain levels]]></title>
      <link>https://rrmacademy.org/library/lowdose-naltrexone-for-the-treatment-of-fibromyalgia-findings-of-a-small-randomi-0vipnvso/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/lowdose-naltrexone-for-the-treatment-of-fibromyalgia-findings-of-a-small-randomi-0vipnvso/</guid>
      <description><![CDATA[Younger J, Noor N, McCue R, Mackey S -- Arthritis &amp; Rheumatism (2013)

AbstractObjectiveTo determine whether low dosages (4.5 mg/day) of naltrexone reduce fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication and extension study of a previous clinical trial, we tested the impact of low‐dose naltrexone on daily self‐reported pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality, and fatigue.

Methods: Thirty‐one women with fibromyalgia participated in the randomized, double‐blind,…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:06 GMT</pubDate>
      <dc:creator><![CDATA[Younger J, Noor N, McCue R, Mackey S]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low Dose Naltrexone in the Treatment of Fibromyalgia]]></title>
      <link>https://rrmacademy.org/library/low-dose-naltrexone-in-the-treatment-of-fibromyalgia-fajhvfsm/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/low-dose-naltrexone-in-the-treatment-of-fibromyalgia-fajhvfsm/</guid>
      <description><![CDATA[Metyas SK, Chen CL, Yeter K, Solyman J, Arkfeld D -- Current Rheumatology Reviews (2018)

Background: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment.

Objective: A significant number of fibromyalgia patients do not respond adequately to the current drugs approved by the Food and Drug Administration (FDA) for fibromyalgia treatment including pregabalin, milnacipran, duloxetine. Thus, there is still a need for adjunctive therapies.

Method: Naltrexone is an opioid receptor antagonist…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:05 GMT</pubDate>
      <dc:creator><![CDATA[Metyas SK, Chen CL, Yeter K, Solyman J, Arkfeld D]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Gender Differences in the Prevalence of Fibromyalgia and in Concomitant Medical and Psychiatric Disorders: A National Veterans Health Administration Study]]></title>
      <link>https://rrmacademy.org/library/gender-differences-in-the-prevalence-of-fibromyalgia-and-in-concomitant-medical--b0jdq4wj/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/gender-differences-in-the-prevalence-of-fibromyalgia-and-in-concomitant-medical--b0jdq4wj/</guid>
      <description><![CDATA[Arout CA, Sofuoglu M, Bastian LA, Rosenheck RA -- Journal of Women's Health (2018)

Background:
Fibromyalgia is a poorly understood, chronically disabling pain syndrome. While research has focused on its clinical presentation and treatment, less is known about fibromyalgia's clinical epidemiology in real-world healthcare systems. Gender differences have been difficult to study because relatively few males are diagnosed with fibromyalgia.


Methods:

Veterans Health Administration (VHA) patients diagnosed with fibromyalgia nationwide in FY 2012 were compared to Veterans with…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:04 GMT</pubDate>
      <dc:creator><![CDATA[Arout CA, Sofuoglu M, Bastian LA, Rosenheck RA]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Effects of long-term therapy with naltrexone on body weight in obesity]]></title>
      <link>https://rrmacademy.org/library/effects-of-longterm-therapy-with-naltrexone-on-body-weight-in-obesity-ln1mlxid/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/effects-of-longterm-therapy-with-naltrexone-on-body-weight-in-obesity-ln1mlxid/</guid>
      <description><![CDATA[Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL -- Clinical Pharmacology and Therapeutics (1985)

The endogenous opiate system is thought to be associated with the regulation of food intake and body weight. Opiate antagonists decrease food intake in animals, but there are no controlled studies in obese man to evaluate body weight response to naltrexone. Sixty obese people were randomized into three groups and given 0, 50, or 100 mg of the opiate antagonist naltrexone for 8 weeks in an outpatient, double-blind study. Weight loss was not significant in either the 50 or 100 mg groups as…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:02 GMT</pubDate>
      <dc:creator><![CDATA[Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Medical management of metabolic dysfunction in PCOS]]></title>
      <link>https://rrmacademy.org/library/medical-management-of-metabolic-dysfunction-in-pcos-tjuwcq5f/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/medical-management-of-metabolic-dysfunction-in-pcos-tjuwcq5f/</guid>
      <description><![CDATA[Duleba AJ -- Steroids (2012)

Polycystic ovary syndrome (PCOS) is associated with metabolic derangements including insulin resistance, dyslipidemia, systemic inflammation and endothelial dysfunction. There is a growing need to develop pharmacologic interventions to improve metabolic function in women with PCOS. Medications that have been tested in patients with PCOS include metformin, thiazolidinediones, acarbose, naltrexone, orlistat, vitamin D and statins. Metformin decreases hepatic gluconeogenesis and free fatty acid…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:08:01 GMT</pubDate>
      <dc:creator><![CDATA[Duleba AJ]]></dc:creator>
      <category>PCOS</category>
    </item>
    <item>
      <title><![CDATA[Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome]]></title>
      <link>https://rrmacademy.org/library/effect-of-longterm-naltrexone-treatment-on-endocrine-profile-clinical-features-a-oqwsthiu/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/effect-of-longterm-naltrexone-treatment-on-endocrine-profile-clinical-features-a-oqwsthiu/</guid>
      <description><![CDATA[Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR -- Fertility and Sterility (2002)]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:59 GMT</pubDate>
      <dc:creator><![CDATA[Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR]]></dc:creator>
      <category>PCOS</category>
    </item>
    <item>
      <title><![CDATA[Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome]]></title>
      <link>https://rrmacademy.org/library/longterm-naltrexone-treatment-normalizes-the-pituitary-response-to-gonadotropinr-fiiqgane/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/longterm-naltrexone-treatment-normalizes-the-pituitary-response-to-gonadotropinr-fiiqgane/</guid>
      <description><![CDATA[Lanzone A, Apa R, Fulghesu AM, Cutillo G, Caruso A, Mancuso S -- Fertility and Sterility (1993)]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:58 GMT</pubDate>
      <dc:creator><![CDATA[Lanzone A, Apa R, Fulghesu AM, Cutillo G, Caruso A, Mancuso S]]></dc:creator>
      <category>PCOS</category>
    </item>
    <item>
      <title><![CDATA[Low dose naltrexone: side effects and efficacy in gastrointestinal disorders]]></title>
      <link>https://rrmacademy.org/library/low-dose-naltrexone-side-effects-and-efficacy-in-gastrointestinal-disorders-l8mnkihf/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/low-dose-naltrexone-side-effects-and-efficacy-in-gastrointestinal-disorders-l8mnkihf/</guid>
      <description><![CDATA[Ploesser J, Weinstock LB, Thomas E -- International journal of pharmaceutical compounding (2010)

1. Int J Pharm Compd. 2010 Mar-Apr;14(2):171-3.

Low dose naltrexone: side effects and efficacy in gastrointestinal disorders.

Ploesser J(1), Weinstock LB, Thomas E.

Author information:
(1)St. Louis College of Pharmacy, St. Louis, Missouri.

Use of low dose naltrexone has been advocated for a variety of medical problems.
Only a few articles published in peer review journals have documented side
effects of low dose naltrexone. The purpose of this study was to determine the
frequency of adverse…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:56 GMT</pubDate>
      <dc:creator><![CDATA[Ploesser J, Weinstock LB, Thomas E]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study]]></title>
      <link>https://rrmacademy.org/library/lowdose-naltreoxone-for-the-treatment-of-irritable-bowel-syndrome-a-pilot-study-ceehxhxd/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/lowdose-naltreoxone-for-the-treatment-of-irritable-bowel-syndrome-a-pilot-study-ceehxhxd/</guid>
      <description><![CDATA[Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z -- Digestive Diseases and Sciences (2006)

Preclinical studies have shown that a very low dose of naltreoxone hydrochloride (NTX), an opiate antagonist, can block excitatory opioid receptors without affecting inhibitory opioid receptors, resulting in analgesic potency without side effects. The present study assessed the efficacy and safety of PTI-901 (low-dose NTX) treatment in Irritable bowel syndrome (IBS) patients. Forty-two IBS patients participated in an open-label study. Participants received 0.5 mg PTI-901/day for 4 weeks and…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:55 GMT</pubDate>
      <dc:creator><![CDATA[Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Sex-Gender Differences in Irritable Bowel Syndrome]]></title>
      <link>https://rrmacademy.org/library/sexgender-differences-in-irritable-bowel-syndrome-x8720cqd/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/sexgender-differences-in-irritable-bowel-syndrome-x8720cqd/</guid>
      <description><![CDATA[Kim YS, Kim N -- Journal of Neurogastroenterology and Motility (2018)

Because of the sex-gender differences that are shown in a diversity of physiological and psychological factors, it can be speculated that the clinical presentation of symptoms as well as treatment strategies in women and men with irritable bowel syndrome (IBS) may differ. Studies have revealed that IBS is more common in women than men. As for the IBS subtype, IBS with constipation is significantly more prevalent among women than men. Sex hormones and gender differences may play important roles…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:53 GMT</pubDate>
      <dc:creator><![CDATA[Kim YS, Kim N]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Vulvodynia: A disease commonly hidden in plain sight]]></title>
      <link>https://rrmacademy.org/library/vulvodynia-a-disease-commonly-hidden-in-plain-sight-svyt4rrp/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/vulvodynia-a-disease-commonly-hidden-in-plain-sight-svyt4rrp/</guid>
      <description><![CDATA[Vieira-Baptista P, Lima-Silva J, Pérez-López FR, Preti M, Bornstein J -- Case Reports in Women's Health (2018)

•Vulvodynia affects at least 6% of women, and can be found at any age and in all ethnic groups.•The diagnosis is one of exclusion but is very often missed.•Women with vulvodynia are frequently misdiagnosed as having vaginismus.•Failure to make the diagnosis often leads to irrelevant or deleterious examinations and treatments.]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:52 GMT</pubDate>
      <dc:creator><![CDATA[Vieira-Baptista P, Lima-Silva J, Pérez-López FR, Preti M, Bornstein J]]></dc:creator>
      <category>Women&apos;s Health</category>
    </item>
    <item>
      <title><![CDATA[Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia]]></title>
      <link>https://rrmacademy.org/library/reduced-proinflammatory-cytokines-after-eight-weeks-of-lowdose-naltrexone-for-fi-gcfphnil/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/reduced-proinflammatory-cytokines-after-eight-weeks-of-lowdose-naltrexone-for-fi-gcfphnil/</guid>
      <description><![CDATA[Parkitny L, Younger J -- Biomedicines (2017)

1. Biomedicines. 2017 Apr 18;5(2):16. doi: 10.3390/biomedicines5020016.

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for
Fibromyalgia.

Parkitny L(1), Younger J(2).

Author information:
(1)Department of Psychology, University of Alabama at Birmingham, Birmingham, AL
35205, USA. lukeparkitny@interleuk.in.
(2)Department of Psychology, University of Alabama at Birmingham, Birmingham, AL
35205, USA. younger@uab.edu.

Fibromyalgia (FM) is a complex, multi-symptom…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:50 GMT</pubDate>
      <dc:creator><![CDATA[Parkitny L, Younger J]]></dc:creator>
      <category>Other</category>
    </item>
    <item>
      <title><![CDATA[Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions]]></title>
      <link>https://rrmacademy.org/library/prevalence-of-symptoms-consistent-with-a-diagnosis-of-vulvodynia-populationbased-gdyejqng/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/prevalence-of-symptoms-consistent-with-a-diagnosis-of-vulvodynia-populationbased-gdyejqng/</guid>
      <description><![CDATA[Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF -- American Journal of Obstetrics and Gynecology (2014)

Objective: We used validated sensitive and specific questions associated with clinically confirmed diagnoses of unexplained vulvar pain (vulvodynia) to compare the cumulative incidence of vulvar pain and prevalence of care-seeking behavior in Boston metropolitan area (BMA) and in Minneapolis/Saint Paul metropolitan area (MSP) from 2001 through 2005 using census-based data, and 2010 through 2012, using outpatient community-clinic data, respectively.

Study design: We received self-administered…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:07:49 GMT</pubDate>
      <dc:creator><![CDATA[Harlow BL, Kunitz CG, Nguyen RH, Rydell SA, Turner RM, MacLehose RF]]></dc:creator>
      <category>Women&apos;s Health</category>
    </item>
    <item>
      <title><![CDATA[Telomere length in offspring is determined by mitochondrial-nuclear communication at fertilization]]></title>
      <link>https://rrmacademy.org/library/telomere-length-in-offspring-is-determined-by-mitochondrialnuclear-communication-zvcmzfco/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/telomere-length-in-offspring-is-determined-by-mitochondrialnuclear-communication-zvcmzfco/</guid>
      <description><![CDATA[Winstanley YE, Rose RD, Sobinoff AP, Wu LL, Adhikari D, Zhang Q, Wells JK, Wong LH, Szeto HH, Piltz SG, Thomas PQ, Febbraio MA, Carroll J, Pickett HA, Russell DL, Robker RL -- Nature Communications (2025)

Abstract
The initial setting of telomere length during early life in each individual has a major influence on lifetime risk of aging-associated diseases; however there is limited knowledge of biological signals that regulate inheritance of telomere length, and whether it is modifiable is not known. We now show that when mitochondrial activity is disrupted in mouse zygotes, via exposure to 20% O2 or rotenone, telomere elongation between the 8-cell and blastocyst stage is impaired, with shorter…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:48 GMT</pubDate>
      <dc:creator><![CDATA[Winstanley YE, Rose RD, Sobinoff AP, Wu LL, Adhikari D, Zhang Q, Wells JK, Wong LH, Szeto HH, Piltz SG, Thomas PQ, Febbraio MA, Carroll J, Pickett HA, Russell DL, Robker RL]]></dc:creator>
      <category>Reproductive Endocrinology</category>
    </item>
    <item>
      <title><![CDATA[Can ovarian aging be delayed by pharmacological strategies?]]></title>
      <link>https://rrmacademy.org/library/can-ovarian-aging-be-delayed-by-pharmacological-strategies-cpsivbkd/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/can-ovarian-aging-be-delayed-by-pharmacological-strategies-cpsivbkd/</guid>
      <description><![CDATA[Zhang J, Chen Q, Du D, Wu T, Wen J, Wu M, Zhang Y, Yan W, Zhou S, Li Y, Jin Y, Luo A, Wang S -- Aging (2019)

1. Aging (Albany NY). 2019 Jan 23;11(2):817-832. doi: 10.18632/aging.101784.

Can ovarian aging be delayed by pharmacological strategies?

Zhang J(1), Chen Q(1), Du D(1), Wu T(1), Wen J(1), Wu M(1), Zhang Y(1), Yan
W(1), Zhou S(1), Li Y(1), Jin Y(1), Luo A(1), Wang S(1).

Author information:
(1)Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Aging has been regarded as a treatable condition,…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:46 GMT</pubDate>
      <dc:creator><![CDATA[Zhang J, Chen Q, Du D, Wu T, Wen J, Wu M, Zhang Y, Yan W, Zhou S, Li Y, Jin Y, Luo A, Wang S]]></dc:creator>
      <category>Reproductive Endocrinology</category>
    </item>
    <item>
      <title><![CDATA[Leukocyte telomere dynamics across gestation in uncomplicated pregnancies and associations with stress]]></title>
      <link>https://rrmacademy.org/library/leukocyte-telomere-dynamics-across-gestation-in-uncomplicated-pregnancies-and-as-dbzi4gr0/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/leukocyte-telomere-dynamics-across-gestation-in-uncomplicated-pregnancies-and-as-dbzi4gr0/</guid>
      <description><![CDATA[Panelli DM, Leonard SA, Wong RJ, Becker M, Mayo JA, Wu E, Girsen AI, Gotlib IH, Aghaeepour N, Druzin ML, Shaw GM, Stevenson DK, Bianco K -- BMC pregnancy and childbirth (2022)

1. BMC Pregnancy Childbirth. 2022 May 2;22(1):381. doi:
10.1186/s12884-022-04693-0.

Leukocyte telomere dynamics across gestation in uncomplicated pregnancies and
associations with stress.

Panelli DM(1), Leonard SA(2), Wong RJ(3), Becker M(3)(4)(5), Mayo JA(3), Wu
E(2), Girsen AI(2), Gotlib IH(6), Aghaeepour N(3)(4)(5), Druzin ML(2), Shaw
GM(3), Stevenson DK(3), Bianco K(2).

Author information:
(1)Department of Obstetrics and Gynecology, Stanford University, 453 Quarry
Road, Palo Alto, CA,…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:45 GMT</pubDate>
      <dc:creator><![CDATA[Panelli DM, Leonard SA, Wong RJ, Becker M, Mayo JA, Wu E, Girsen AI, Gotlib IH, Aghaeepour N, Druzin ML, Shaw GM, Stevenson DK, Bianco K]]></dc:creator>
      <category>Pregnancy</category>
    </item>
    <item>
      <title><![CDATA[How to Reduce the Potential Harmful Effects of Light on Blastocyst Development during IVF]]></title>
      <link>https://rrmacademy.org/library/how-to-reduce-the-potential-harmful-effects-of-light-on-blastocyst-development-d-lka3thsj/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/how-to-reduce-the-potential-harmful-effects-of-light-on-blastocyst-development-d-lka3thsj/</guid>
      <description><![CDATA[Bódis J, Gödöny K, Várnagy Á, Kovács K, Koppán M, Nagy B, Erostyák J, Herczeg R, Szekeres-Barthó J, Gyenesei A, Kovács GL -- Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2020)

1. Med Princ Pract. 2020;29(6):558-564. doi: 10.1159/000509016. Epub 2020 May 29.

How to Reduce the Potential Harmful Effects of Light on Blastocyst Development
during IVF.

Bódis J(1)(2), Gödöny K(1)(2), Várnagy Á(1)(2), Kovács K(1)(2), Koppán M(1)(2),
Nagy B(3)(4), Erostyák J(5)(6), Herczeg R(6), Szekeres-Barthó J(2)(6), Gyenesei
A(6), Kovács GL(2)(6)(7).

Author information:
(1)Department of Obstetrics and Gynecology, University of Pécs, Pécs, Hungary.
(2)MTA-PTE Human Reproduction…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:43 GMT</pubDate>
      <dc:creator><![CDATA[Bódis J, Gödöny K, Várnagy Á, Kovács K, Koppán M, Nagy B, Erostyák J, Herczeg R, Szekeres-Barthó J, Gyenesei A, Kovács GL]]></dc:creator>
      <category>Reproductive Endocrinology</category>
    </item>
    <item>
      <title><![CDATA[Leukocyte telomere length in children born following blastocyst-stage embryo transfer]]></title>
      <link>https://rrmacademy.org/library/leukocyte-telomere-length-in-children-born-following-blastocyststage-embryo-tran-hvyzrtml/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/leukocyte-telomere-length-in-children-born-following-blastocyststage-embryo-tran-hvyzrtml/</guid>
      <description><![CDATA[Wang C, Gu Y, Zhou J, Zang J, Ling X, Li H, Hu L, Xu B, Zhang B, Qin N, Lv H, Duan W, Jiang Y, He Y, Jiang T, Chen C, Han X, Zhou K, Xu B, Liu X, Tao S, Jiang Y, Du J, Dai J, Diao F, Lu C, Guo X, Huo R, Liu J, Lin Y, Xia Y, Jin G, Ma H, Shen H, Hu Z -- Nature medicine (2022)

1. Nat Med. 2022 Dec;28(12):2646-2653. doi: 10.1038/s41591-022-02108-3. Epub 2022
Dec 15.

Leukocyte telomere length in children born following blastocyst-stage embryo
transfer.

Wang C(#)(1)(2)(3), Gu Y(#)(1)(2), Zhou J(#)(2), Zang J(#)(2), Ling X(#)(1)(4),
Li H(#)(1)(5), Hu L(6), Xu B(7), Zhang B(8), Qin N(1)(2), Lv H(1)(9), Duan W(3),
Jiang Y(1)(2), He Y(1)(2), Jiang T(1)(10), Chen C(2), Han X(1)(2), Zhou K(1)(2),
Xu B(1)(2), Liu X(1)(2), Tao S(1)(2), Jiang Y(1)(2), Du J(1)(2), Dai J(1)(2),…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:41 GMT</pubDate>
      <dc:creator><![CDATA[Wang C, Gu Y, Zhou J, Zang J, Ling X, Li H, Hu L, Xu B, Zhang B, Qin N, Lv H, Duan W, Jiang Y, He Y, Jiang T, Chen C, Han X, Zhou K, Xu B, Liu X, Tao S, Jiang Y, Du J, Dai J, Diao F, Lu C, Guo X, Huo R, Liu J, Lin Y, Xia Y, Jin G, Ma H, Shen H, Hu Z]]></dc:creator>
      <category>Pregnancy</category>
    </item>
    <item>
      <title><![CDATA[Use of a mouse in vitro fertilization model to understand the developmental origins of health and disease hypothesis]]></title>
      <link>https://rrmacademy.org/library/use-of-a-mouse-in-vitro-fertilization-model-to-understand-the-developmental-orig-vu85nmnc/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/use-of-a-mouse-in-vitro-fertilization-model-to-understand-the-developmental-orig-vu85nmnc/</guid>
      <description><![CDATA[Feuer SK, Liu X, Donjacour A, Lin W, Simbulan RK, Giritharan G, Piane LD, Kolahi K, Ameri K, Maltepe E, Rinaudo PF -- Endocrinology (2014)

1. Endocrinology. 2014 May;155(5):1956-69. doi: 10.1210/en.2013-2081. Epub 2014
Mar 31.

Use of a mouse in vitro fertilization model to understand the developmental
origins of health and disease hypothesis.

Feuer SK(1), Liu X, Donjacour A, Lin W, Simbulan RK, Giritharan G, Piane LD,
Kolahi K, Ameri K, Maltepe E, Rinaudo PF.

Author information:
(1)Department of Obstetrics, Gynecology and Reproductive Sciences (S.K.F., X.L.,
A.D., W.L., R.K.S., G.G., L.D.P., K.K., P.F.R.), and Department of…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:39 GMT</pubDate>
      <dc:creator><![CDATA[Feuer SK, Liu X, Donjacour A, Lin W, Simbulan RK, Giritharan G, Piane LD, Kolahi K, Ameri K, Maltepe E, Rinaudo PF]]></dc:creator>
      <category>Reproductive Endocrinology</category>
    </item>
    <item>
      <title><![CDATA[Prevalence and performance of private equity-affiliated fertility practices in the United States]]></title>
      <link>https://rrmacademy.org/library/prevalence-and-performance-of-private-equityaffiliated-fertility-practices-in-th-hcyrwhff/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/prevalence-and-performance-of-private-equityaffiliated-fertility-practices-in-th-hcyrwhff/</guid>
      <description><![CDATA[Borsa A, Bruch JD -- Fertility and sterility (2022)

1. Fertil Steril. 2022 Jan;117(1):124-130. doi: 10.1016/j.fertnstert.2021.08.035.
Epub 2021 Sep 15.

Prevalence and performance of private equity-affiliated fertility practices in
the United States.

Borsa A(1), Bruch JD(2).

Author information:
(1)Department of Sociomedical Sciences, Columbia University Mailman School of
Public Health, New York, New York. Electronic address:
asb2266@cumc.columbia.edu.
(2)Department of Health Care Policy, Harvard Medical School, Boston,
Massachusetts.

Comment…]]></description>
      <pubDate>Thu, 18 Jun 2026 22:02:37 GMT</pubDate>
      <dc:creator><![CDATA[Borsa A, Bruch JD]]></dc:creator>
      <category>Economics</category>
    </item>
    <item>
      <title><![CDATA[Chapter 15: Scientific Foundations of the CrMS]]></title>
      <link>https://rrmacademy.org/library/chapter-15-scientific-foundations-of-the-crms-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-15-scientific-foundations-of-the-crms-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

The CREIGHTON MODEL FertilityCare System (CrMS) rests on a decades-long body of research demonstrating that cervical mucus functions as a physiologically regulated biological valve, opening predictably at the periovulatory estrogen rise and closing in the post-Peak phase. Chapter 15 of Hilgers (2004) synthesizes hormonal, ultrasound, cytologic, and biophysical evidence to establish that a woman's external observation of her Peak Day reliably identifies the fertile window, and documents the…]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>Fertility Awareness</category>
    </item>
    <item>
      <title><![CDATA[Chapter 43: Polycystic Ovarian Disease]]></title>
      <link>https://rrmacademy.org/library/chapter-43-polycystic-ovarian-disease-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-43-polycystic-ovarian-disease-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

PCOS (polycystic ovary syndrome), increasingly designated PMOS (polycystic metabolic ovary syndrome) to reflect its metabolic complexity, is far more prevalent than its classic presentation suggests, affecting roughly six percent of reproductive-age women and carrying systemic consequences well beyond fertility disruption. This chapter from the foundational NaProTECHNOLOGY textbook maps the hormonal architecture of the condition, its ovulatory defect patterns, its frequent co-occurrence with…]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>PCOS</category>
    </item>
    <item>
      <title><![CDATA[Chapter 47: Male Infertility: Evaluation and Treatment]]></title>
      <link>https://rrmacademy.org/library/chapter-47-male-infertility-evaluation-and-treatment-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-47-male-infertility-evaluation-and-treatment-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

Male infertility plays a clinically significant role in a large share of couples who struggle to conceive, yet standard laboratory criteria for semen analysis were designed primarily to predict success with assisted reproduction, not natural fertility. NaProTECHNOLOGY approaches male factor as a diagnosable condition with identifiable root causes, applying medical and surgical options aimed at restoring sperm function and combining that work with fertility-awareness charting to maximize the…]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[Chapter 56: Prevention of Preterm Birth]]></title>
      <link>https://rrmacademy.org/library/chapter-56-prevention-of-preterm-birth-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-56-prevention-of-preterm-birth-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

Preterm birth remains a leading cause of perinatal mortality, with rates in the United States rising significantly over the latter half of the twentieth century despite decades of awareness. NaProTechnology's integrated prevention approach, developed at the Pope Paul VI Institute, addresses this problem through systematic risk stratification, hormonal support, infection surveillance, and cervical monitoring across the full course of pregnancy.]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>Pregnancy</category>
    </item>
    <item>
      <title><![CDATA[Chapter 6: Introductory Presentation of the CrMS]]></title>
      <link>https://rrmacademy.org/library/chapter-6-introductory-presentation-of-the-crms-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-6-introductory-presentation-of-the-crms-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

This 2004 textbook chapter by Thomas W. Hilgers outlines the structure and content of the formal introductory session used to enroll couples in the Creighton Model FertilityCare System (CrMS). It covers the biological foundation of fertility charting, the role of cervical mucus as a biomarker of the reproductive cycle, and the educational framework designed to train couples in systematic, real-time cycle observation.]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>NaProTECHNOLOGY</category>
    </item>
    <item>
      <title><![CDATA[Chapter 13: Achieving- and Avoiding-Related Behavior (Use)]]></title>
      <link>https://rrmacademy.org/library/chapter-13-achieving-and-avoiding-related-behavior-use-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-13-achieving-and-avoiding-related-behavior-use-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

Chapter 13 of Hilgers' NaProTECHNOLOGY textbook establishes a clinical behavioral taxonomy unique to the Creighton Model FertilityCare System, distinguishing between achieving-related and avoiding-related use based on whether a couple's actions increase or decrease the probability of conception. The chapter argues that a "taking a chance" mindset is inherently contraceptive in psychology and must be replaced with intentional, education-grounded behavior that reflects a couple's genuine family…]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>Fertility Awareness</category>
    </item>
    <item>
      <title><![CDATA[Chapter 34: Cancer: NaProTECHNOLOGY and Early Detection]]></title>
      <link>https://rrmacademy.org/library/chapter-34-cancer-naprotechnology-and-early-detection-hilgers2004/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/chapter-34-cancer-naprotechnology-and-early-detection-hilgers2004/</guid>
      <description><![CDATA[Hilgers TW -- The Medical and Surgical Practice of NaProTECHNOLOGY (2004)

Chapter 34 of Hilgers (2004) examines how NaProTechnology cycle charting may identify women at elevated risk for three gynecologic cancers: endometrial, breast, and ovarian. The chapter presents clinical case series and a small prospective study suggesting that observable cycle biomarkers, particularly patterns indicating suboptimal luteal-phase function, may precede diagnosis and could inform earlier evaluation, while calling explicitly for further research to validate these findings.]]></description>
      <pubDate>Mon, 15 Jun 2026 18:35:05 GMT</pubDate>
      <dc:creator><![CDATA[Hilgers TW]]></dc:creator>
      <category>Women&apos;s Health</category>
    </item>
    <item>
      <title><![CDATA[Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites]]></title>
      <link>https://rrmacademy.org/library/altered-semen-quality-in-relation-to-urinary-concentrations-of-phthalate-monoest-gjtxqtlr/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/altered-semen-quality-in-relation-to-urinary-concentrations-of-phthalate-monoest-gjtxqtlr/</guid>
      <description><![CDATA[Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM -- Epidemiology (Cambridge, Mass.) (2006)

BACKGROUND: Phthalates are multifunctional chemicals used in a variety of consumer, medical, and personal care products. Previously, we reported dose-response associations of decreased semen quality with urinary concentrations of monobutyl phthalate (MBP) and monobenzyl (MBzP) phthalate, which are metabolites of dibutyl phthalate and butylbenzyl phthalate, respectively. The present study extends our work in a larger sample of men and includes measurements of di(2-ethylhexyl) phthalate (DEHP)…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:18:42 GMT</pubDate>
      <dc:creator><![CDATA[Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[Raman Microspectroscopy evidence of microplastics in human semen]]></title>
      <link>https://rrmacademy.org/library/raman-microspectroscopy-evidence-of-microplastics-in-human-semen-v8xqmuxx/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/raman-microspectroscopy-evidence-of-microplastics-in-human-semen-v8xqmuxx/</guid>
      <description><![CDATA[Montano L, Giorgini E, Notarstefano V, Notari T, Ricciardi M, Piscopo M, Motta O -- The Science of the total environment (2023)

The presence of microplastics (MPs) in human fluids and organs is a great concern, since, as highlighted by recent studies on animal models, they could cause alterations of several physiological functions, including reproduction. In this study, semen samples collected from men living in a polluted area of the Campania Region (Southern Italy), were analyzed to assess the presence of MPs. N. 16 pigmented microplastic fragments (ranging from 2 to 6 μm in size) with spheric or irregular shapes were…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:18:36 GMT</pubDate>
      <dc:creator><![CDATA[Montano L, Giorgini E, Notarstefano V, Notari T, Ricciardi M, Piscopo M, Motta O]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[Association of mixed exposure to microplastics with sperm dysfunction: a multi-site study in China]]></title>
      <link>https://rrmacademy.org/library/association-of-mixed-exposure-to-microplastics-with-sperm-dysfunction-a-multisit-xfsiinhv/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/association-of-mixed-exposure-to-microplastics-with-sperm-dysfunction-a-multisit-xfsiinhv/</guid>
      <description><![CDATA[Zhang C, Zhang G, Sun K, Ren J, Zhou J, Liu X, Lin F, Yang H, Cao J, Nie L, Zhang P, Zhang L, Wang Z, Guo H, Lin X, Duan S, Cao J, Huang H -- EBioMedicine (2024)

BACKGROUND: Microplastics are environmental pollutants detected in various human organs and tissues. These particles originate from multiple sources including the degradation of larger plastic items and the intentional inclusion in consumer goods. Potential risks for human health resulting from microplastics exposure have also been reported. However, the distribution in the male reproductive system and its effect remains largely unknown. This study aims to investigate the presence of multiple…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:18:30 GMT</pubDate>
      <dc:creator><![CDATA[Zhang C, Zhang G, Sun K, Ren J, Zhou J, Liu X, Lin F, Yang H, Cao J, Nie L, Zhang P, Zhang L, Wang Z, Guo H, Lin X, Duan S, Cao J, Huang H]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[Detection and characterization of microplastics in the human testis and semen]]></title>
      <link>https://rrmacademy.org/library/detection-and-characterization-of-microplastics-in-the-human-testis-and-semen-7wkj9bw3/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/detection-and-characterization-of-microplastics-in-the-human-testis-and-semen-7wkj9bw3/</guid>
      <description><![CDATA[Zhao Q, Zhu L, Weng J, Jin Z, Cao Y, Jiang H, Zhang Z -- The Science of the total environment (2023)

The health risk of microplastics (MPs) is a growing global concern. Evidence of reproductive health damage caused by the accumulation of MPs in males is still lacking. In the present study, 6 testis and 30 semen samples were collected, and MPs were detected using both pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) and laser direct infrared spectroscopy (LD-IR). The results showed that MPs were detected in both testis and semen, with an average abundance of 0.23 ± 0.45 particles/mL in…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:18:24 GMT</pubDate>
      <dc:creator><![CDATA[Zhao Q, Zhu L, Weng J, Jin Z, Cao Y, Jiang H, Zhang Z]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[The Presence of Microplastics in Human Semen and Their Associations with Semen Quality]]></title>
      <link>https://rrmacademy.org/library/the-presence-of-microplastics-in-human-semen-and-their-associations-with-semen-q-r0smihyv/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/the-presence-of-microplastics-in-human-semen-and-their-associations-with-semen-q-r0smihyv/</guid>
      <description><![CDATA[Guo Y, Rong M, Fan Y, Teng X, Jin L, Zhao Y -- Toxics (2025)

Microplastics (MPs) are becoming one of the most serious environmental threats worldwide. They have been shown to induce male reproductive toxicity in animal studies. However, evidence of their adverse effects on male reproductive health in human is still lacking. In this study, we evaluated the presence of MPs in human semen and explored their associations with semen quality. A total of 45 semen samples from men attending a fertility center were collected. MPs in the semen samples were…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:18:19 GMT</pubDate>
      <dc:creator><![CDATA[Guo Y, Rong M, Fan Y, Teng X, Jin L, Zhao Y]]></dc:creator>
      <category>Andrology/Male Factor</category>
    </item>
    <item>
      <title><![CDATA[Protocol for PRP Use at Surgery: SOP for Fertility PRP Injection in Gynecologic Surgery]]></title>
      <link>https://rrmacademy.org/library/protocol-for-prp-use-at-surgery-sop-for-fertility-prp-injection-in-gynecologic-s-vcm5rrvl/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/protocol-for-prp-use-at-surgery-sop-for-fertility-prp-injection-in-gynecologic-s-vcm5rrvl/</guid>
      <description><![CDATA[Naomi Whittaker -- IIRRM Grand Rounds (2026)

A standard operating procedure (SOP) for platelet-rich plasma (PRP) injection into the ovaries, cervix, and uterus during gynecologic surgery. Covers patient selection and contraindications, PRP preparation using 80-120 mL venous blood with dual-spin centrifugation, and injection techniques for ovarian intraovarian injection (4 cc per ovary with calcium activation), uterine/endometrial infusion, and cervical injection. Indications include diminished ovarian reserve, thin/refractory endometrium,…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:15:05 GMT</pubDate>
      <dc:creator><![CDATA[Naomi Whittaker]]></dc:creator>
      <category>Surgery</category>
    </item>
    <item>
      <title><![CDATA[Systematic review and meta-analysis of polycystic ovary syndrome and mental health among Black Asian Minority Ethnic populations]]></title>
      <link>https://rrmacademy.org/library/systematic-review-and-metaanalysis-of-polycystic-ovary-syndrome-and-mental-healt-fsyhavas/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/systematic-review-and-metaanalysis-of-polycystic-ovary-syndrome-and-mental-healt-fsyhavas/</guid>
      <description><![CDATA[Delanerolle G, Ayis S, Barzilova V, Phiri P, Jagadeesan P, Zeng Y, Ranaweera S, Shetty A, Haque N, Kar D, Majumder K, Rathod S, Raymont V, Shi JQ, Hapangama DK -- Academia Mental Health and Well-Being (2025)

Background: Polycystic ovary syndrome (PCOS) is a common, chronic gynaecological condition impacting women of reproductive age. Women with PCOS have hormonal, ovulatory, and metabolic dysfunction resulting in multiple symptoms. The correlation between hormonal disbalance and mental health outcomes in PCOS across Black Asian Minority Ethnic populations was investigated in this systematic review and meta-analysis. The review included 30 studies and data from nearly 4,000 women with PCOS. Major…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:14:29 GMT</pubDate>
      <dc:creator><![CDATA[Delanerolle G, Ayis S, Barzilova V, Phiri P, Jagadeesan P, Zeng Y, Ranaweera S, Shetty A, Haque N, Kar D, Majumder K, Rathod S, Raymont V, Shi JQ, Hapangama DK]]></dc:creator>
      <category>PCOS</category>
    </item>
    <item>
      <title><![CDATA[Causes of infertility as predictors of subsequent cancer risk]]></title>
      <link>https://rrmacademy.org/library/causes-of-infertility-as-predictors-of-subsequent-cancer-risk-xjag5v5s/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/causes-of-infertility-as-predictors-of-subsequent-cancer-risk-xjag5v5s/</guid>
      <description><![CDATA[Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Moghissi KS, Scoccia B -- Epidemiology (2005)

Large retrospective cohort study investigating whether different causes of infertility (endometriosis, anovulation, tubal disease, male factor, cervical/uterine disorders) predict future cancer risk among 12,193 women who sought infertility treatment at five U.S. reproductive endocrinology practices between 1965 and 1988, with cancer incidence tracked through 1999.]]></description>
      <pubDate>Mon, 15 Jun 2026 05:11:08 GMT</pubDate>
      <dc:creator><![CDATA[Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Moghissi KS, Scoccia B]]></dc:creator>
      <category>Infertility</category>
    </item>
    <item>
      <title><![CDATA[Preconception TSH and pregnancy outcomes: a population-based cohort study in 184 611 women]]></title>
      <link>https://rrmacademy.org/library/preconception-tsh-and-pregnancy-outcomes-a-populationbased-cohort-study-in-184-6-ilumz1sf/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/preconception-tsh-and-pregnancy-outcomes-a-populationbased-cohort-study-in-184-6-ilumz1sf/</guid>
      <description><![CDATA[Chen S, Zhou X, Zhu H, Yang H, Gong F, Wang L, Zhang M, Jiang Y, Yan C, Li J, Wang Q, Zhang S, Pan H -- Clinical Endocrinology (2017)

This population-based cohort study examined preconception TSH levels and their association with pregnancy outcomes in 184,611 Chinese women planning to conceive. Women were classified into reference (0.48-2.49 mIU/L), upper limit (2.5-4.28 mIU/L), and high TSH (4.29-10 mIU/L) groups. The high normal TSH group showed higher rates of spontaneous abortion, preterm birth, and operative vaginal delivery compared to reference. The high TSH group had higher rates of spontaneous abortion, stillbirth,…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:11:05 GMT</pubDate>
      <dc:creator><![CDATA[Chen S, Zhou X, Zhu H, Yang H, Gong F, Wang L, Zhang M, Jiang Y, Yan C, Li J, Wang Q, Zhang S, Pan H]]></dc:creator>
      <category>Pregnancy</category>
    </item>
    <item>
      <title><![CDATA[Assessing the effect of introducing a new method into family planning programs in India, Peru, and Rwanda]]></title>
      <link>https://rrmacademy.org/library/assessing-the-effect-of-introducing-a-new-method-into-family-planning-programs-i-gp0wtgjf/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/assessing-the-effect-of-introducing-a-new-method-into-family-planning-programs-i-gp0wtgjf/</guid>
      <description><![CDATA[Lundgren R, Sinai I, Jha P, Mukabatsinda M, Sacieta L, León FR -- Reproductive Health (2012)

Background: Introducing a new method into family planning programs requires careful attention to ensure it meets an actual need and has a positive effect on program goals. The Standard Days Method® is a fertility awareness-based method of family planning that is being introduced into family planning programs in countries around the world. It is different from other methods offered by programs, and may bring new couples into family planning, and increase contraceptive prevalence. The study…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:09:58 GMT</pubDate>
      <dc:creator><![CDATA[Lundgren R, Sinai I, Jha P, Mukabatsinda M, Sacieta L, León FR]]></dc:creator>
      <category>Fertility Awareness</category>
    </item>
    <item>
      <title><![CDATA[Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option]]></title>
      <link>https://rrmacademy.org/library/universal-cervicallength-screening-and-vaginal-progesterone-prevents-early-prete-m5eqoaun/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/universal-cervicallength-screening-and-vaginal-progesterone-prevents-early-prete-m5eqoaun/</guid>
      <description><![CDATA[Campbell S -- Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2011)]]></description>
      <pubDate>Mon, 15 Jun 2026 05:09:33 GMT</pubDate>
      <dc:creator><![CDATA[Campbell S]]></dc:creator>
      <category>Pregnancy</category>
    </item>
    <item>
      <title><![CDATA[Unexplained recurrent pregnancy loss and unexplained infertility: twins in disguise]]></title>
      <link>https://rrmacademy.org/library/unexplained-recurrent-pregnancy-loss-and-unexplained-infertility-twins-in-disgui-twewhiyf/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/unexplained-recurrent-pregnancy-loss-and-unexplained-infertility-twins-in-disgui-twewhiyf/</guid>
      <description><![CDATA[Fox CW, Savaris RF, Jeong JW, et al. -- Human Reproduction Open (2020)

Endometrial BCL6 protein levels are significantly elevated in women with unexplained recurrent pregnancy loss and unexplained infertility compared with fertile controls, with 79% of subfertile women displaying elevated BCL6. Among those with abnormal BCL6 who underwent laparoscopy, most were found to have endometriosis, suggesting a continuum of progesterone resistance and inflammatory/endometriosis-related endometrial dysfunction.]]></description>
      <pubDate>Mon, 15 Jun 2026 05:07:24 GMT</pubDate>
      <dc:creator><![CDATA[Fox CW, Savaris RF, Jeong JW, et al.]]></dc:creator>
      <category>Endometriosis</category>
    </item>
    <item>
      <title><![CDATA[Incidence, prevalence, and trends in endometriosis diagnosis: a United States population-based study from 2006 to 2015]]></title>
      <link>https://rrmacademy.org/library/incidence-prevalence-and-trends-in-endometriosis-diagnosis-a-united-states-popul-bg6nupge/</link>
      <guid isPermaLink="true">https://rrmacademy.org/library/incidence-prevalence-and-trends-in-endometriosis-diagnosis-a-united-states-popul-bg6nupge/</guid>
      <description><![CDATA[Christ JP, Yu O, Schulze-Rath R, Grafton J, Hansen K, Reed SD -- American journal of obstetrics and gynecology (2021)

BACKGROUND: Accurate estimates of incidence and prevalence of endometriosis among nonselected cohorts are lacking in the United States, and earlier reports have produced varying results.

OBJECTIVE: This study aimed to define endometriosis incidence and prevalence in a US population and evaluate factors influencing these estimates over time.

STUDY DESIGN: A 10-year retrospective cohort study using Kaiser Permanente Washington electronic health records database was completed. The primary…]]></description>
      <pubDate>Mon, 15 Jun 2026 05:06:18 GMT</pubDate>
      <dc:creator><![CDATA[Christ JP, Yu O, Schulze-Rath R, Grafton J, Hansen K, Reed SD]]></dc:creator>
      <category>Endometriosis</category>
    </item>
  </channel>
</rss>